IL-15 is recognized as a promising candidate for tumor immunotherapy and has been described as both a promoter of cancer and a promoter of anti-cancer immunity. IL-15 was discovered in cells transformed by HTLV-1, the etiologic agent of adult T cell leukemia/lymphoma (ATL) and the human retrovirus that carries the Tax oncogene. We have developed the TAX-LUC mouse model of ATL in which Tax expression drives both malignant transformation and luciferase expression, enabling non-invasive imaging of tumorigenesis in real time. To identify the role of IL-15 in spontaneous development of lymphoma in vivo, an IL-15？/？ TAX-LUC strain was developed and examined. The absence of IL-15 resulted in aggressive tumor growth and accelerated mortality and demonstrated that IL-15 was not required for Tax-mediated lymphoma but was essential for anti-tumor immunity. Further analysis revealed a unique transcriptional profile in tumor cells that arise in the absence of IL-15 that included a significant increase in the expression of IL-1α and IL-1α-regulated cytokines. Moreover, anti-IL-1α antibodies and an IL-1 receptor antagonist (Anakinra) were used to interrogate the potential of IL-1α targeted therapies in this model. Taken together, these findings identify IL-15 and IL-1α as therapeutic targets in lymphoma.
References
[1]
Gillgrass A, Ashkar A (2011) Stimulating natural killer cells to protect against cancer: recent developments. Expert Rev Clin Immunol 7: 367–82.
[2]
Jakobisiak M, Golab J, Lasek W (2011) Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 22: 99–108.
[3]
Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, et al. (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191: 771–80.
[4]
Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, et al. (1994) A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 91: 4935–9.
[5]
Bamford R, Battiata A, Burton J, Sharma H, Waldmann T (1996) Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc Natl Acad Sci U S A 93: 2897–902.
[6]
Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, et al. (2009) Interleukin-15 enhances proteasomal degradation of Bid in normal lymphocytes. Implications for large granular lymphocyte leukemias. Cancer Res 69: 3986–3994.
[7]
Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, et al. (2008) Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 112: 770–781.
[8]
Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, et al. (2003) Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 9: 4802–4810.
[9]
Trentin L, Cerutti A, Zambello R, Sancretta R, Tassinari C, et al. (1996) Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 87: 3327–3335.
[10]
Sato N, Sabzevari H, Fu S, Petrus MN, Bamford RN, et al. (2011) Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα. Blood 117: 4032–40.
[11]
Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, et al. (2012) Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 22: 645–55.
[12]
Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA (1998) Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci U S A 95: 2452–7.
[13]
Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L (1995) Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A. 92: 1057–61.
[14]
Rauch D, Gross S, Harding J, Niewiesk S, Lairmore M, et al. (2009) Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood 113: 1493–500.
[15]
Rauch D, Gross S, Harding J, Bokhari S, Niewiesk S, et al. (2009) T cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology 6: 116.
[16]
Portis T, Harding J, Ratner L (2001) The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood 98: 1200–8.
[17]
Gao L, Deng H, Zhao H, Hirbe A, Harding J, et al. (2005) HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106: 4294–302.
[18]
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519–50.
[19]
Dvorkin T, Song X, Argov S, White RM, Zoller M, et al. (2006) Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1α. J Leukoc Biol 80: 96–106.
[20]
Ben-Sasson SZ, Caucheteux S, Crank M, Hu-Li J, Paul W (2011) IL-1 acts on T cells to enhance the magnitude of in vivo immune responses. Cytokine 56: 122–5.
[21]
Song X, Voronov E, Dvorkin T, Fima E, Cagnano D, et al. (2003) Differential effects of IL-1 alpha and IL-1β on tumorigenicity patterns and invasiveness. J Immunol 171: 6448–56.
[22]
Apte RN, Dotan S, Elkabets M, White MR, Reich E, et al. (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387–408.
[23]
Apte RN, Dvorkin T, Song X, Fima E, Krelin Y, et al. (2000) Opposing effects of IL-1 alpha and IL-1β on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness. Adv Exp Med Biol 479: 277–88.
[24]
Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, et al. (2009) Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholanthrene tumor cells. J Immunol 182: 4874–81.
[25]
Nazarenko I, Marhaba R, Reich E, Voronov E, Vitacolonna M, et al. (2008) Tumorigenicity of IL-1alpha- and IL-1 beta-deficient fibrosarcoma cells. Neoplasia 10: 549–62.
[26]
Marhaba R, Nazarenko I, Kn？fler D, Reich E, Voronov E, et al. (2008) Opposing effects of fibrosarcoma cell-derived IL-1 alpha and IL-1 beta on immune response induction. Int J Cancer 123: 134–45.
[27]
Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, et al. (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1 beta-secreting cells. J Immunol 175: 8200–8.
[28]
Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, et al. (2010) Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A 107: 2574–9.
[29]
Buryskova M, Pospisek M, Grothey A, Simmet T, Burysek L (2004) Intracellular interleukin-1alpha functionally interacts with histone acetyltransferase complexes. J Biol Chem 279: 4017–26.
[30]
Werman A, Werman-Venkert R, White R, Lee JK, Werman B, et al. (2004) The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 101: 2434–9.
[31]
Rider P, Kaplanov I, Romzova M, Bernardis L, Braiman A, et al. (2012) The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. Front Immunol 3: 290.
[32]
Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, et al. (2011) IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 187: 4835–43.
[33]
Goon PK, Biancardi A, Fast N, Igakura T, Hanon E, et al. (2004) Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J Infect Dis 189: 2294–8.
[34]
Rowan AG, Bangham CR (2012) Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma? Leuk Res Treatment 2012: 391953 doi: 10.1155/2012/391953.
[35]
Pique C, Connan F, Levilain JP, Choppin J, Dokhélar MC (1996) Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response. J Virol 70: 4919–26.
[36]
Mori N, Prager D (1996) Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood 87: 3410–7.
[37]
Nakayama Y, Ishikawa C, Tamaki K, Senba M, Fujita J, Mori N (2011) Interleukin-1 alpha produced by human T-cell leukaemia virus type I-infected T cells induces intercellular adhesion molecule-1 expression on lung epithelial cells. J Med Microbiol 60: 1750–61.
[38]
Sagawa K, Mochizuki M, Katagirl K, Tsuboi I, Sugita S, et al. (1996) In vitro effects of immunosuppressive agents on cytokine production by HTLV-I-infected T cell clones derived from the ocular fluid of patients with HTLV-I uveitis. Microbiol Immunol 40: 373–9.
[39]
Kurihara K, Harashima N, Hanabuchi S, Masuda M, Utsunomiya A, et al. (2005) Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer 114: 257–67.
[40]
Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, et al. (2004) Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 109: 559–67.
[41]
Wano Y, Hattori T, Matsuoka M, Takatsuki K, Chua AO, et al. (1987) Interleukin 1 gene expression in adult T cell leukemia. J Clin Invest 80: 911–6.
[42]
Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, et al. (2006) The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 12: 1088–96.
[43]
Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y (2002) Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 46: 533–44.
[44]
Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, et al. (2012) IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Res Treat 136: 659–71.
[45]
Luedke E, Jaime-Ramirez AC, Bhave N, Rhoda J, Choudhary MM, et al. (2012) Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152: 431–40.
[46]
Moga E, Cantó E, Vidal S, Juarez C, Sierra J, Briones J (2011) Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. Exp Hematol 39: 1064–71.
[47]
Zhang M, Yao Z, Dubois S, Ju W, Müller JR, Waldmann TA (2009) Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A 106: 7513–8.
[48]
Zhang M, Ju W, Yao Z, Yu P, Wei BR, et al. (2012) Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol 188: 6156–64.
[49]
Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, et al. (2009) Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A 106: 19455–60.
[50]
Hong DS, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, et al. (2011) Abstract A211: A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. Molecular Cancer Therapeutics 10: Supplement 1. doi: 10.1158/1535-7163. TARG-11-A211.
